KB Insurance Expands Cancer Coverage to Include Targeted Anticancer Drugs, Radiation, and Hormonal Medications

On the 5th, KB Insurance announced the launch of KB Cancer Insurance, which includes coverage for four new medical technologies: targeted anticancer drug authorized treatment, targeted anticancer radiation treatment, specific anticancer hormone drug authorized treatment, and thyroid cancer hormone drug authorized treatment.

[Asia Economy Reporter Oh Hyung-gil] KB Insurance announced on the 5th that it will launch KB Cancer Insurance, which incorporates all four new medical technology coverages: targeted anticancer drug authorized treatment, targeted anticancer radiation treatment, specific anticancer hormone drug authorized treatment, and thyroid cancer hormone drug authorized treatment.

To provide coverage for thyroid hormone medication, which most patients must take after thyroid cancer surgery, the 'Thyroid Cancer Hormone Drug Authorized Treatment Fee' launched in January has obtained exclusive usage rights.

Recent cases have shown that combining systemic treatment with anticancer drugs and localized treatment with radiation simultaneously can improve treatment effectiveness for highly aggressive cancers that rapidly spread throughout the body, such as advanced liver cancer and lung cancer.

The 'Targeted Anticancer Radiation Treatment Fee,' which covers both targeted anticancer drug authorized treatment and targeted anticancer radiation treatment, guarantees intensity modulated radiation therapy (IMRT).

Intensity modulated radiation therapy is a treatment method that precisely adjusts radiation compared to conventional radiation therapy, differentiating the radiation dose distribution between the affected area and normal cells to minimize side effects and aftereffects.

Additionally, coverage ranges from preventive protection for precancerous stages confirmed through health checkups, such as benign tumor and polyp diagnosis fees for the stomach, duodenum, and colon, as well as benign tumor and polyp diagnosis fees for six major organs, to 'Cancer-Specific Pain Relief Treatment Fee,' 'Cancer-Specific Rehabilitation Treatment Fee,' and 'Terminal Cancer Hospice Pain Relief Treatment Fee' for pain relief and rehabilitation after cancer treatment.

KB Insurance's new cancer insurance sales, which were about 200 million KRW per month on average, increased eightfold to 1.6 billion KRW per month on average after the launch of the targeted anticancer drug authorized treatment fee last year.

A KB Insurance official stated, "With the advancement of medical technology, consumers can prepare for relatively expensive medical expenses through insurance, reducing their treatment cost burden while improving treatment effectiveness and quality of life. We will continue to develop innovative products that can lead the market by reflecting diverse customer needs."